Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
<p>Abstract</p> <p>Background</p> <p>Orphan drugs are a growing issue of importance to European healthcare policy makers. The success of orphan drug legislation in Europe has resulted in an increasing number of licensed medicines for rare diseases, and many more yet unl...
Main Authors: | Milanova Tsveta, Schey Carina, Hutchings Adam |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-09-01
|
Series: | Orphanet Journal of Rare Diseases |
Online Access: | http://www.ojrd.com/content/6/1/62 |
Similar Items
-
Access to Affordable Orphan Medicines in Europe: An EHA Position Paper
by: Giampaolo Merlini, et al.
Published: (2020-10-01) -
Trends in orphan medicinal products approvals in the European Union between 2010–2022
by: Luísa Bouwman, et al.
Published: (2024-02-01) -
A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01) -
Orphan drugs Authors' reply to BioMarin Europe
by: Nicholl, D, et al.
Published: (2011) -
Making Sure That Orphan Incentives Tip the Right Way in Europe
by: Denis Horgan, et al.
Published: (2022-08-01)